We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
-4.2%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$130M
AUM Growth
-$25.5M
Cap. Flow
-$11.9M
Cap. Flow %
-9.14%
Top 10 Hldgs %
100%
Holding
11
New
–
Increased
1
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$118K

Top Sells

Rank Stock Value
1
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$8.81B
$59.9M 46.04%
793,036
– –
INZY
2
DELISTED
Inozyme Pharma
INZY
$20M 15.41%
4,494,851
– –
OCS icon
3
Oculis Holding
OCS
$708M
$19.1M 14.66%
1,595,918
– –
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.3B
$19M 14.59%
2,041,108
+13,100
+0.6% +$118K
EXAI
5
DELISTED
Exscientia Plc American Depositary Shares
EXAI
$3.93M 3.02%
770,500
– –
RLYB icon
6
Rallybio
RLYB
$87M
$3.22M 2.48%
300,581
– –
VIGL
7
DELISTED
Vigil Neuroscience
VIGL
$2.24M 1.72%
560,595
– –
BOLT icon
8
Bolt Biotherapeutics
BOLT
$7.65M
$1.42M 1.09%
94,573
– –
IOBT
9
DELISTED
IO Biotech
IOBT
$1.01M 0.78%
864,197
– –
ALGS icon
10
Aligos Therapeutics
ALGS
$45.5M
$260K 0.2%
29,729
– –
FUSN
11
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
– –
-563,385
Closed -$12M

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SL
SOF Ltd George Town, Cayman Islands $279M AUM 6.12% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $279M AUM 45.74% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q2 2024 Portfolio in Review

As of Q2 2024, Pivotal bioVenture Partners Investment Advisor held 11 positions worth $130M, down 16% from $156M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Pivotal bioVenture Partners Investment Advisor withdrew a net $11.9M in Q2 2024, closing 1 position. Its most notable exit was Fusion Pharmaceuticals Inc. Common Shares, an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Pivotal bioVenture Partners Investment Advisor added an estimated $118K to Arcutis Biotherapeutics.

  • Pivotal bioVenture Partners Investment Advisor added most to Arcutis Biotherapeutics in Q2 2024, an estimated $118K increase.
  • Pivotal bioVenture Partners Investment Advisor fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $12M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 100% of its $130M portfolio in Q2 2024.
  • Pivotal bioVenture Partners Investment Advisor opened 0 new positions and closed 1 in Q2 2024.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value fell 16% quarter-over-quarter to $130M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q2 2024, filed 13 Aug 2024.